Edgewise reports Q2 net loss $0.32/sh; positive EDG-5506 BMD interim data

Edgewise Therapeutics, Inc.

2022-Q2 EPS reported -$0.62

Cash and equivalents $248.4M as of June 30; expected to fund operations through end of 2024.
Net loss $16.1M ($0.32/sh) for Q2 2022 vs $14.7M ($0.30/sh) prior quarter.
ARCH study: CK reduced 30%, TNNI2 reduced 68% after 2 months of EDG-5506 10 mg daily.
Enrolling CANYON Phase 2 trial of EDG-5506 in BMD; plan to start Phase 2 in DMD in 2022.
Preclinical EDG-002 program for HCM advancing; IND-enabling studies planned in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.